### MORGAN STANLEY RESEARCH ASIA/PACIFIC

Morgan Stanley India Company Private Limited+

### Mangesh Bhadang

Mangesh.Bhadang@morganstanley.com +91 22 2209 7073

### Akshay Soni

Akshay.Soni@morganstanley.com +91 22 2209 7151

September 22, 2008

## India Cement Demand Slowdown in North; Price Hikes in South

**Volumes up only 3.8%, pricing up 2.5%:** August 2008 saw the imbalance in the regional demand supply situation increase with weak demand and pricing growth in the North and strong demand and price hikes in the South. The all-India demand growth slumped to 3.8% led by 9% volume declines in the North. Capacity utilization hit a three-year low of 77% (Exhibit 1), which was down 11% YoY and 9% MoM. We expect prices to come down significantly in the North given the excessive capacity additions in the region.

### **Significant demand slowdown in the North:** Demand in the Northern region declined by 9% YoY on the back of a slowdown in housing activity. Although YoY demand was down due to the high base effect, MoM cement dispatches were also down by 11%. The Northern region has seen the addition of more than 12 mn tons of capacity in the last six months, which is 23% of its existing capacity. We expect the dual factors of the demand slowdown as well as increasing supply to lead to a significant pricing decline in the North over the next six months. Amongst our coverage, Ambuja has the highest exposure to the Northern Region (Exhibit 18).


**Demand and pricing growth remain strong in Southern region:** Demand in the South at 10.3% continued its strong growth pattern exhibited over the last 2-3 years. Prices in the region increased by 3.9% with cities like Chennai, Hyderabad and Bangalore showed price increases of Rs15, Rs12.5, and Rs5 per 50kg bag, respectively. Ultratech has the highest exposure to the Southern markets, and its new capacity at *tadipatri* is coming up in the same region giving it a slight advantage over the Northern players.

**Key Triggers:** Grasim's 4.5mn ton Shambhupura plant will start dispatches in early October, which we believe will put tremendous pressure on pricing in the North.

### **Companies Featured**

Rating
Underweight
Underweight
Equal-weight
Underweight Morgan Stanley Research

### Exhibit 1 India Cement Capacity Utilization at lowest levels in the last three years



Source: CMA, Company data, Morgan Stanley Research.

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

# For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Industry View Cautious

September 22, 2008 India Cement


## India Cement – August 2008 Performance

Exhibit 2 All India Cement Prices (Rs per 50kg bag) 250 238 234 240 236 232 230 230 223 220 210 20 200 190 180 170 Aug-07 Dec-07 Feb-08 Mar-08 Sep-07 Nov-07 Jan-08 Apr-08 Jun-08 Jul-08 Feb-07 Mar-07 Apr-07 May-07 Jun-07 Jul-07 Oct-07 May-08 Aug-08 07 Jan-


Source: CMA Morgan Stanley Re


Exhibit 3

### Regional Change in Prices (YoY change)




Source: CMA, Company data, Morgan Stanley Research Exhibit 4






Source: CMA, Company data, Morgan Stanley Research

### Exhibit 5 India Cement Capacity Utilization at Lowest Levels in the Last Three Years




### All India Demand Growth Slows



Source: CMA, Company data, Morgan Stanley Research Exhibit 7


### Price Hikes in Southern Cities (Rs per bag)



Source: CMA, Company data, Morgan Stanley Research


September 22, 2008 India Cement

## **Regional Demand**




Source: CMA, Company data, Morgan Stanley Research

Exhibit 9




Source: CMA, Company data, Morgan Stanley Research

### Exhibit 10 Moderate Demand Growth in Western Region (%YoY)



Source: CMA, Company data, Morgan Stanley Research




Source: CMA, Company data, Morgan Stanley Research


**Pricing Discipline** 

### MORGAN STANLEY RESEARCH

September 22, 2008 India Cement




Source: CMA, Company data, Morgan Stanley Research




Source: CMA, Company data, Morgan Stanley Research

### Exhibit 14 Southern Region



Source: CMA, Company data, Morgan Stanley Research



Source: CMA, Company data, Morgan Stanley Research

September 22, 2008 India Cement




India Cement - August 2008

Source: CMA, Company data, Morgan Stanley Research

Exhibit 17 **Capacity Addition in the Last Two Quarters** 25% 22.8% Capacity addition (as % of current capacity) in the last 2 quarters 20% 15.7% 15.3% 13.3% 15% 9.1% 10% 5% 0% North West Total South East


Source: CMA, Company data, Morgan Stanley Research

### Exhibit 18 Ambuja Has Highest Exposure to North and Least to South



Source: Company data, Morgan Stanley Research

Exhibit 19



Source: Bloomberg, Morgan Stanley Research

September 22, 2008 India Cement

Disclosure Section The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 20008434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 20008434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia financial concises licence No. 222742, which accepts responsibility for Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia financial concises licence No. 222742, which accepts the concentry), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia financial concises licence No. 222742, which accepts the concentry), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia financial concises licence No. 222742, which accepts the concentry), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia Concentry), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia Concentry), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia Limited (A.B.N. 67 003 734 576, holder of Australia Concentry), and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australia Limited (A.B.N. 67 003 734 576, holder of Australia Limited (A.B.N. 67 003 734 576, holder of Australia Limited (A.B.N. 67 003 734 576, holder of Australia Limited (A.B.N. 67 003 734 576, holder of Austral Limited (A.B.N. 67 003 734 576, holder of Austral Lim

Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley"). For important disclosures, stock price charts and rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Equity Research Management), New York, NY, 10036 USA.

### Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Mangesh Bhadang. Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

### **Global Research Conflict Management Policy**

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

### Important US Regulatory Disclosures on Subject Companies

As of August 29, 2008, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: ACC Ltd., Ambuja Cements Ltd., Grasim Industries. In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Grasim Industries. Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Grasim Industries. Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Ultratech Cement Ltd. The research analysts, strategists, or research associates principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. An employee or director of Morgan Stanley & Co. Incorporated is a director of Ambuja Cements Ltd.. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

### STOCK RATINGS

SIGN RATINGS Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight and Underweight are not the equivalent of Buy, Hold and Sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

### **Global Stock Ratings Distribution**

### (as of August 31, 2008)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight to hold and Underweight to sell recommendations, respectively.

	Coverage Universe		Investment	Banking Clie	ents (IBC)
-		% of		% of %	% of Rating
Stock Rating Category	Count	Total	Count	Total IBC	Category
Overweight/Buy	892	41%	299	45%	34%
Equal-weight/Hold	936	43%	277	42%	30%
Underweight/Sell	367	17%	87	13%	24%
Total	2,195		663		

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley or an affiliate received investment banking compensation in the last 12 months.

### **Analyst Stock Ratings**

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months. Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months. Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months. Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

More volatile (V) - We estimate that this stock has more than a 25% chance of a price move (up or down) of more than 25% in a month, based on a with the past three years. Stocks with less than one year of trading history are automatically rated as more volatile (unless otherwise noted). We note that securities that we do not currently consider "more volatile" can still perform in that manner. Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

September 22, 2008 India Cement

### **Analyst Industry Views**

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below. In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

### **Other Important Disclosures**

Morgan Stanley produces a research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in this or other research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

For a discussion, if applicable, of the valuation methods used to determine the price targets included in this summary and the risks related to achieving these targets, please refer to the latest relevant published research on these stocks.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities/instruments discussed in Morgan Stanley Research may not be suitable for all investors. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies The discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities or derivatives of securities of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities or derivatives of securities of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons

Morgan Stanley and its affiliate companies do business that relates to companies/instruments covered in Morgan Stanley Research, including market making and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis.

With the exception of information regarding Morgan Stanley, research prepared by Morgan Stanley Research personnel are based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits

The value of and income from your investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in your securities transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. Unless otherwise stated, the cover page provides the closing price on the primary exchange for the subject company's securities/instruments.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. Information on securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK") is Hang Seng China Enterprise Index; or any securities/instruments issued by a company that is 30% or more directly- or indirectly-owned by the government of or a company incorporated in the PRC and traded on an exchange in Hong Kong or Macau, namely SEHK's Red Chip shares, including the component company of the SEHK's China-affiliated Corp Index is distributed only to Taiwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment documents and is a company that distributed to the public media or uptilic media or uptilic media or uptilic media. their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives. Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan

Stanley Asia Limited

Stanley Asia Limited. Morgan Stanley Research is disseminated in Japan by Morgan Stanley Japan Securities Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 1992/062982) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services licence No. 233742, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International plc representative about the investments concerned. In Australia, Morgan Stanley Private U.K. investors should obtai Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International plc representative about the investors should obtain the advice of their Morgan Stanley & Co. International plc representative about the investors Act. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at wholesale customers only, as defined by the DFSA. This research will only be made available to a wholesale customer who we are satisfied meets the regulatory criteria to be a client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

### MORGAN STANLEY RESEARCH

September 22, 2008 India Cement

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion hereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

**The Americas** 1585 Broadway New York, NY 10036-8293 **United States** Tel: +1 (1) 212 761 4000

### Europe 20 Bank Street, Canary Wharf London E14 4AD United Kingdom Tel: +44 (0) 20 7 425 8000

Japan 4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan Tel: +81 (0) 3 5424 5000

### Asia/Pacific Three Exchange Square Central Hong Kong Tel: +852 2848 5200

### Industry Coverage:India Cement

Company (Ticker)	Rating (as of) Price (09/22/2008)		
Mangesh Bhadang			
ACC Ltd. (ACC.BO)	U (08/25/2008)	Rs624.5	
Ambuja Cements Ltd. (ABUJ.BO)	U (08/25/2008)	Rs84.55	
Grasim Industries (GRAS.BO)	E (08/25/2008)	Rs1,937.2	
Ultratech Cement Ltd (ULTC.BO)	U (08/25/2008)	Rs556	

Stock Ratings are subject to change. Please see latest research for each company.